Photon Therapeutics Ltd
07396990
Healthy
- No accounts filed in last 18 months (-5)
Details
Compliance
Last accounts
31/10/2024
total exemption full
Next accounts due
31/07/2026
Confirmation statement
Last: 11/01/2026
Due 25/01/2027
Industry
Officers
director · Since 05/10/2010
CONSULTANT OPHTHALMIC SURGEON
BRITISH · UNITED KINGDOM · Age 63
Also on 13 other boards
director · Since 18/02/2019
DIRECTOR
IRISH · ENGLAND · Age 62
Also on 1 other board
Persons with Significant Control
Mr Simon John Dean
New Zealander · New Zealand · Age 53
86-90, Paul Street, London, EC2A 4NE
Notified 23/07/2018
Mr Sunil Shah
British · United Kingdom · Age 63
86-90, Paul Street, London, EC2A 4NE
Notified 29/10/2023
Former PSCs
Mr Sunil Shah
Ceased 20/11/2022
CompanyRankvs 15+ SIC 26600 peers84
Show leaderboard
How is this score calculated?
Net worth compared to all companies in the same SIC code with published accounts. Top quartile earns the full 25 points.
Workforce size relative to sector peers from the most recent accounts. A larger team generally signals commercial scale.
Current assets ÷ current liabilities. A ratio above 2× earns full marks; between 1–2× scores partially; below 0.5× scores minimal points.
One point per year of operation since incorporation, capped at 15. Older companies have a proven track record.
Full 15 points when both annual accounts and confirmation statement are filed on time. Points are deducted for each overdue filing.
Maximum score is 100. Deductions apply for insolvency history, outstanding charges, going concern doubt, or disqualified officers.
Key FinancialsYear ending 31/10/2024
Net Worth
£449k
Balance sheet strength
Cash
£388k
Cash in the bank
Net Current Assets
£448k
Working capital
Current Assets
£459k
Current Liabilities
£12k
Fixed Assets
£1k
Debtors
£71k
Director Loans
Balance Sheet
EstimatesDerived
| Year | Current Ratio | Implied Profit |
|---|---|---|
| 2024 | 39.43 | -£287k |
| 2023 | 20.60 | -£426k |
| 2022 | — | +£1.4M |
| 2021 | — | -£208k |
Derived from filed accounts. Not audited figures.